152 related articles for article (PubMed ID: 37831172)
1. Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS).
Zhang M; Xie W; Li J; Zheng J; Zhou Y
Arch Womens Ment Health; 2024 Feb; 27(1):35-44. PubMed ID: 37831172
[TBL] [Abstract][Full Text] [Related]
2. Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression.
Cooper MC; Kilvert HS; Hodgkins P; Roskell NS; Eldar-Lissai A
CNS Drugs; 2019 Oct; 33(10):1039-1052. PubMed ID: 31642037
[TBL] [Abstract][Full Text] [Related]
3. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.
Powell JG; Garland S; Preston K; Piszczatoski C
Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884
[No Abstract] [Full Text] [Related]
4. Brexanolone for the treatment of patients with postpartum depression.
Morrison KE; Cole AB; Thompson SM; Bale TL
Drugs Today (Barc); 2019 Sep; 55(9):537-544. PubMed ID: 31584571
[TBL] [Abstract][Full Text] [Related]
5. Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Mazhar F; Pozzi M; Gentili M; Scatigna M; Clementi E; Radice S; Carnovale C
CNS Drugs; 2019 Jun; 33(6):581-592. PubMed ID: 30977109
[TBL] [Abstract][Full Text] [Related]
6. Brexanolone for postpartum depression.
Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States.
Eldar-Lissai A; Cohen JT; Meltzer-Brody S; Gerbasi ME; Chertavian E; Hodgkins P; Bond JC; Johnson SJ
J Manag Care Spec Pharm; 2020 May; 26(5):627-638. PubMed ID: 32191592
[TBL] [Abstract][Full Text] [Related]
8. Brexanolone Is the First Drug Specifically for Postpartum Depression.
Fantasia HC
Nurs Womens Health; 2019 Oct; 23(5):450-454. PubMed ID: 31445988
[TBL] [Abstract][Full Text] [Related]
9. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.
Leader LD; O'Connell M; VandenBerg A
Pharmacotherapy; 2019 Nov; 39(11):1105-1112. PubMed ID: 31514247
[TBL] [Abstract][Full Text] [Related]
10. Brexanolone: A Novel Drug for the Treatment of Postpartum Depression.
Patatanian E; Nguyen DR
J Pharm Pract; 2022 Jun; 35(3):431-436. PubMed ID: 33302791
[TBL] [Abstract][Full Text] [Related]
11. Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data.
Garafola S; Shiferaw E; Dev V
Drugs Real World Outcomes; 2023 Sep; 10(3):351-356. PubMed ID: 37280463
[TBL] [Abstract][Full Text] [Related]
12. Treating postpartum depression with brexanolone.
Burval J; Kerns R; Reed K
Nursing; 2020 May; 50(5):48-53. PubMed ID: 32332506
[TBL] [Abstract][Full Text] [Related]
13. Brexanolone (Zulresso) for postpartum depression.
Med Lett Drugs Ther; 2019 May; 61(1571):68-70. PubMed ID: 31169804
[No Abstract] [Full Text] [Related]
14. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S
Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236
[TBL] [Abstract][Full Text] [Related]
15. Brexanolone to Treat Postpartum Depression in Adult Women.
Cornett EM; Rando L; Labbé AM; Perkins W; Kaye AM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2021 Mar; 51(2):115-130. PubMed ID: 34092826
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
17. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.
Wang Y; Lin Y; Lin Q; Liang H; Cai W; Jiang D
Sci Rep; 2023 Jul; 13(1):12257. PubMed ID: 37507539
[TBL] [Abstract][Full Text] [Related]
18. Implementation of a Hospital-based Brexanolone Program.
Howard MM; Diaz Z; Battle CL
J Psychiatr Pract; 2022 Sep; 28(5):404-408. PubMed ID: 36074110
[TBL] [Abstract][Full Text] [Related]
19. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
Shu Y; Chen J; Ding Y; Zhang Q
Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
[TBL] [Abstract][Full Text] [Related]
20. Serotonin syndrome: A pharmacovigilance comparative study of drugs affecting serotonin levels.
Elli C; Novella A; Pasina L
Eur J Clin Pharmacol; 2024 Feb; 80(2):231-237. PubMed ID: 38032391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
